Yuri Kimura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yuri Kimura has a total of 68 co-authors. Here are the top co-authors by number of shared publications:
- Shinsuke Sasada
Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
6 shared publications - Morihito Okada
Department of Surgical Oncology, Hiroshima University, Hiroshima, Japan
4 shared publications Akiko Emi
Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
3 shared publications- Akiko Emi
Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan
3 shared publications - Emi Taniguchi
Breast Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
3 shared publications Kazuyo Yoshida
3 shared publications
Latest Publications
- Open Access
- 12 November 2026
- Published by Elsevier in The Breast
- Vol. 91
Time to maximal response of trastuzumab deruxtecan in patients with HER2-Positive metastatic breast cancer: A multicenter retrospective study (TRACE)
- 12 November 2026
- Published by Elsevier in The Breast
- Vol. 91
Open AccessTime to maximal response of trastuzumab deruxtecan in patients with HER2-Positive metastatic breast cancer: A multicenter retrospective study (TRACE)
- Open Access
- 11 September 2026
- Published by Elsevier in SSRN Electronic Journal
Time to Maximal Response of Trastuzumab Deruxtecan in Patients with HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study (TRACE)
Background: Trastuzumab deruxtecan (T-DXd) has demonstrated transformative efficacy in HER2-positive metastatic breast cancer (MBC), and induction–maintenance strategies with T-DXd are under investigation to optimize the treatments. Understanding the time to maximal response (TTMR) is important for optimizing induction duration. However, real-world data on TTMR with T-DXd remain limited.Methods: TRACE is a multicenter, retrospective observational study. Patients with histologically confirmed HER2-positive MBC who received T-DXd between 2020 and 2025 were eligible. The primary endpoint was TTMR, defined as the time from T-DXd initiation to the nadir of target lesion sum of diameters, assessed according to RECIST v1.1. Patients with progressive disease as best overall response, stable disease without tumor shrinkage, or no evaluable target lesions were excluded.Results: Of 125 patients identified, 93 were eligible for the primary analysis. The median age was 60 years; 62% had hormone receptor-positive disease, and 66% received T-DXd in the third line or later. The median TTMR was 4.57 months (95% CI: 3.73–5.60). No significant difference in TTMR was observed by subgroups. Best overall response was CR in 9%, PR in 74%, and SD in 17%. Spider plot analysis showed a median tumor burden change of −2.7% beyond 18 weeks.Conclusions: In this real-world multicenter cohort, T-DXd achieved maximal tumor shrinkage at a median of 4.57 months in patients with HER2-positive MBC. Tumor burden change beyond 18 weeks was minimal at the population level, suggesting limited additional benefit from continued T-DXd. These findings may inform future maintenance strategies in HER2-positive MBC.
- 11 September 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessTime to Maximal Response of Trastuzumab Deruxtecan in Patients with HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study (TRACE)
Background: Trastuzumab deruxtecan (T-DXd) has demonstrated transformative efficacy in HER2-positive metastatic breast cancer (MBC), and induction–maintenance strategies with T-DXd are under investigation to optimize the treatments. Understanding the time to maximal response (TTMR) is important for optimizing induction duration. However, real-world data on TTMR with T-DXd remain limited.Methods: TRACE is a multicenter, retrospective observational study. Patients with histologically confirmed HER2-positive MBC who received T-DXd between 2020 and 2025 were eligible. The primary endpoint was TTMR, defined as the time from T-DXd initiation to the nadir of target lesion sum of diameters, assessed according to RECIST v1.1. Patients with progressive disease as best overall response, stable disease without tumor shrinkage, or no evaluable target lesions were excluded.Results: Of 125 patients identified, 93 were eligible for the primary analysis. The median age was 60 years; 62% had hormone receptor-positive disease, and 66% received T-DXd in the third line or later. The median TTMR was 4.57 months (95% CI: 3.73–5.60). No significant difference in TTMR was observed by subgroups. Best overall response was CR in 9%, PR in 74%, and SD in 17%. Spider plot analysis showed a median tumor burden change of −2.7% beyond 18 weeks.Conclusions: In this real-world multicenter cohort, T-DXd achieved maximal tumor shrinkage at a median of 4.57 months in patients with HER2-positive MBC. Tumor burden change beyond 18 weeks was minimal at the population level, suggesting limited additional benefit from continued T-DXd. These findings may inform future maintenance strategies in HER2-positive MBC.
- Open Access
- 1 September 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 9 (9) , e2500182
Development and Validation of an Ipsilateral Breast Tumor Recurrence Risk Estimation Tool Incorporating Real-World Data and Evidence From Meta-Analyses: A Retrospective Multicenter Cohort Study
PURPOSE: Ipsilateral breast tumor recurrence (IBTR) remains a critical concern for patients undergoing breast-conserving surgery (BCS). Reliable risk estimation tools for IBTR risk can support personalized surgical and adjuvant treatment decisions, especially in the era of evolving systemic therapies. We aimed to develop and validate models to estimate IBTR risk. PATIENTS AND METHODS: This multicenter retrospective cohort study included 8,938 women who underwent partial mastectomy for invasive breast cancer between 2008 and 2017. Prediction models were developed using Cox proportional hazards regression and validated via bootstrap resampling. Model performance was assessed using Harrell's C-index, Brier scores, calibration plots, and goodness-of-fit tests. RESULTS: During a median follow-up of 9.0 years (IQR, 6.6-10.9), IBTR occurred in 320 patients (3.6%). The initial model, based on variables from Sanghani et al, achieved a Harrell's C-index of 0.74. Incorporating hormonal receptor status, human epidermal growth factor receptor 2 status, radiotherapy, and targeted therapy as predictors reduced the C-index to 0.65, despite their clinical relevance. Importantly, the inclusion of these factors improved calibration, demonstrating better alignment between predicted and observed IBTR probabilities. Although the hazard ratios (HRs) for radiotherapy aligned with the Early Breast Cancer Trialists’ Collaborative Group meta-analyses (MA), those for chemotherapy and endocrine therapy showed slight differences. Therefore, HRs from the MA were used to represent treatment effects in our model. CONCLUSION: We have developed and internally validated a new risk estimation model for IBTR using Cox regression and bootstrap methods. A Web-based risk estimation tool is now available to facilitate individualized risk assessment and treatment planning.
- 1 September 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 9 (9) , e2500182
Open AccessDevelopment and Validation of an Ipsilateral Breast Tumor Recurrence Risk Estimation Tool Incorporating Real-World Data and Evidence From Meta-Analyses: A Retrospective Multicenter Cohort Study
PURPOSE: Ipsilateral breast tumor recurrence (IBTR) remains a critical concern for patients undergoing breast-conserving surgery (BCS). Reliable risk estimation tools for IBTR risk can support personalized surgical and adjuvant treatment decisions, especially in the era of evolving systemic therapies. We aimed to develop and validate models to estimate IBTR risk. PATIENTS AND METHODS: This multicenter retrospective cohort study included 8,938 women who underwent partial mastectomy for invasive breast cancer between 2008 and 2017. Prediction models were developed using Cox proportional hazards regression and validated via bootstrap resampling. Model performance was assessed using Harrell's C-index, Brier scores, calibration plots, and goodness-of-fit tests. RESULTS: During a median follow-up of 9.0 years (IQR, 6.6-10.9), IBTR occurred in 320 patients (3.6%). The initial model, based on variables from Sanghani et al, achieved a Harrell's C-index of 0.74. Incorporating hormonal receptor status, human epidermal growth factor receptor 2 status, radiotherapy, and targeted therapy as predictors reduced the C-index to 0.65, despite their clinical relevance. Importantly, the inclusion of these factors improved calibration, demonstrating better alignment between predicted and observed IBTR probabilities. Although the hazard ratios (HRs) for radiotherapy aligned with the Early Breast Cancer Trialists’ Collaborative Group meta-analyses (MA), those for chemotherapy and endocrine therapy showed slight differences. Therefore, HRs from the MA were used to represent treatment effects in our model. CONCLUSION: We have developed and internally validated a new risk estimation model for IBTR using Cox regression and bootstrap methods. A Web-based risk estimation tool is now available to facilitate individualized risk assessment and treatment planning.
- 1 March 2023
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 83 (5_Suppleme) , P3-04
Abstract P3-04-10: The TILs-US score adding vascularity assessment based on ultrasonography for predicting tumor-infiltrating lymphocytes in human epidermal growth factor receptor 2-positive and triple-negative breast cancer
Background: Tumor-infiltrating lymphocytes (TILs) are a useful prognostic factor and predictive biomarker of neoadjuvant chemotherapy treatment response for breast cancer, especially in human epidermal growth factor receptor type 2 (HER2)-positive breast cancer and triple-negative breast cancer (TNBC). However, due to heterogeneity of TIL expression and distribution in the tissues, accurately predicting TIL expression, especially using limited core-needle biopsy specimens, is difficult. Therefore, an accurate and simple preoperative evaluation method is needed. We have reported that the TILs-ultrasonography (US) score determined by characteristic US findings has a predictive performance for lymphocyte-predominant breast cancer (LPBC). This study aimed to investigate whether the TILs-US score with added vascularity assessment has a better predictive performance for LPBC. Methods: This multicenter, retrospective study investigated the validation and scoring of the LPBC characteristic imaging findings and applied it for LPBC and non-LPBC prediction. A total of 100 patients with HER2-positive breast cancer (n = 59) and TNBC (n = 41) treated by curative surgery between January 2014 and December 2021 were evaluated. Stromal lymphocytes in surgical pathological specimens were evaluated; the cutoff value for predicting LPBC was defined as ≥50% stromal TILs. Preoperative US was examined for TIL indicators. The US images with characteristic TILs were scored for LPBC prediction. Univariate and multivariate logistic regression analyses were employed for each potential predictor variable of LPBC. Results: A total of 40 patients with ≥50% stromal TILs were defined as having LPBC. The examined characteristic US findings for predicting LPBC, shape (more lobulated), internal echo level (weaker), posterior echoes (stronger), and vascularity assessment (hypervascularity), were significantly associated with LPBC and used to assign the scoring for predicting LPBC. As previously reported, the TILs-US score ranged from 0–7 points based on three ultrasonic tissue characteristics: shape (round, oval, and polygonal or irregular, 0 points; lobulated, 1 point; and small lobulated, 2 points), internal echo level (high or equal, 0 points; low, 1 point; and extremely low, 2 points), and posterior echoes (shadowing or attenuating, 0 points; no change, 1 point; accentuated, 2 points; and extremely accentuated, 3 points). We further added vascularity assessment (avascular or hypovascular, 0 point; moderately vascular, 1 point; and hypervascular, 2 points) to this scoring system. Based on the receiver operating characteristics (ROC) curves (AUC [Area Under the Curve] 0.77), the score cutoff for predicting LPBC was 4 points for TILs-US score (sensitivity, 0.83; specificity, 0.55; and accuracy, 0.66). Multivariate logistic regression analysis revealed that cT (< T2), estrogen receptor (ER) negativity, and a TILs-US score of ≥4 points were significant LPBC predictors (odds ratio [OR] 3.60; p = 0.028; OR 8.68; p = 0.020; OR 5.99; p = 0.005). Conversely, based on the ROC curves (AUC 0.78), the score cutoff for predicting LPBC was 5 points after adding vascularity assessment (sensitivity, 0.93; specificity, 0.57; and accuracy, 0.71). Multivariate logistic regression analysis revealed that cT (< T2), ER negativity, and a TILs-US score adding vascularity assessment of ≥5 points were significant LPBC predictors (OR 5.12; p = 0.010; OR 10.3; p = 0.019; OR 20.1; p < 0.001). Conclusions: Including the vascularity assessment to the TILs-US score, which can be noninvasively obtained using US, is a more accurate preoperative predictor of LPBC. Vascularity assessment may be an auxiliary factor in predicting LPBC. Citation Format: Yuri Kimura, Norio Masumoto, Sadako Akashi-Tanaka, Kayo Fukui, Midori Noma, Aya Nagata, Takashi Nakamura, Hiroaki Shima, Toshitaka Okuno, Akari Murakami, Yoshiaki Kamei, Shogo Nakano, Koji Arihiro. The TILs-US score adding vascularity assessment based on ultrasonography for predicting tumor-infiltrating lymphocytes in human epidermal growth factor receptor 2-positive and triple-negative breast cancer [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P3-04-10.
- 1 March 2023
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 83 (5_Suppleme) , P3-04
Abstract P3-04-10: The TILs-US score adding vascularity assessment based on ultrasonography for predicting tumor-infiltrating lymphocytes in human epidermal growth factor receptor 2-positive and triple-negative breast cancer
Background: Tumor-infiltrating lymphocytes (TILs) are a useful prognostic factor and predictive biomarker of neoadjuvant chemotherapy treatment response for breast cancer, especially in human epidermal growth factor receptor type 2 (HER2)-positive breast cancer and triple-negative breast cancer (TNBC). However, due to heterogeneity of TIL expression and distribution in the tissues, accurately predicting TIL expression, especially using limited core-needle biopsy specimens, is difficult. Therefore, an accurate and simple preoperative evaluation method is needed. We have reported that the TILs-ultrasonography (US) score determined by characteristic US findings has a predictive performance for lymphocyte-predominant breast cancer (LPBC). This study aimed to investigate whether the TILs-US score with added vascularity assessment has a better predictive performance for LPBC. Methods: This multicenter, retrospective study investigated the validation and scoring of the LPBC characteristic imaging findings and applied it for LPBC and non-LPBC prediction. A total of 100 patients with HER2-positive breast cancer (n = 59) and TNBC (n = 41) treated by curative surgery between January 2014 and December 2021 were evaluated. Stromal lymphocytes in surgical pathological specimens were evaluated; the cutoff value for predicting LPBC was defined as ≥50% stromal TILs. Preoperative US was examined for TIL indicators. The US images with characteristic TILs were scored for LPBC prediction. Univariate and multivariate logistic regression analyses were employed for each potential predictor variable of LPBC. Results: A total of 40 patients with ≥50% stromal TILs were defined as having LPBC. The examined characteristic US findings for predicting LPBC, shape (more lobulated), internal echo level (weaker), posterior echoes (stronger), and vascularity assessment (hypervascularity), were significantly associated with LPBC and used to assign the scoring for predicting LPBC. As previously reported, the TILs-US score ranged from 0–7 points based on three ultrasonic tissue characteristics: shape (round, oval, and polygonal or irregular, 0 points; lobulated, 1 point; and small lobulated, 2 points), internal echo level (high or equal, 0 points; low, 1 point; and extremely low, 2 points), and posterior echoes (shadowing or attenuating, 0 points; no change, 1 point; accentuated, 2 points; and extremely accentuated, 3 points). We further added vascularity assessment (avascular or hypovascular, 0 point; moderately vascular, 1 point; and hypervascular, 2 points) to this scoring system. Based on the receiver operating characteristics (ROC) curves (AUC [Area Under the Curve] 0.77), the score cutoff for predicting LPBC was 4 points for TILs-US score (sensitivity, 0.83; specificity, 0.55; and accuracy, 0.66). Multivariate logistic regression analysis revealed that cT (< T2), estrogen receptor (ER) negativity, and a TILs-US score of ≥4 points were significant LPBC predictors (odds ratio [OR] 3.60; p = 0.028; OR 8.68; p = 0.020; OR 5.99; p = 0.005). Conversely, based on the ROC curves (AUC 0.78), the score cutoff for predicting LPBC was 5 points after adding vascularity assessment (sensitivity, 0.93; specificity, 0.57; and accuracy, 0.71). Multivariate logistic regression analysis revealed that cT (< T2), ER negativity, and a TILs-US score adding vascularity assessment of ≥5 points were significant LPBC predictors (OR 5.12; p = 0.010; OR 10.3; p = 0.019; OR 20.1; p < 0.001). Conclusions: Including the vascularity assessment to the TILs-US score, which can be noninvasively obtained using US, is a more accurate preoperative predictor of LPBC. Vascularity assessment may be an auxiliary factor in predicting LPBC. Citation Format: Yuri Kimura, Norio Masumoto, Sadako Akashi-Tanaka, Kayo Fukui, Midori Noma, Aya Nagata, Takashi Nakamura, Hiroaki Shima, Toshitaka Okuno, Akari Murakami, Yoshiaki Kamei, Shogo Nakano, Koji Arihiro. The TILs-US score adding vascularity assessment based on ultrasonography for predicting tumor-infiltrating lymphocytes in human epidermal growth factor receptor 2-positive and triple-negative breast cancer [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P3-04-10.
- 21 October 2022
- Published by Springer Nature in Breast Cancer
- Vol. 30 (1) , 151-155
Impact of oral hygiene on febrile neutropenia during breast cancer chemotherapy
Purpose Oral hygiene is crucial in the management of oral and febrile complications during chemotherapy for cancer. This study aimed to investigate the impact of oral hygiene on the incidence of febrile neutropenia (FN) throughout the course of chemotherapy for breast cancer. Methods A total of 137 patients with breast cancer who underwent four cycles of adjuvant chemotherapy with docetaxel and cyclophosphamide (TC) combination therapy or docetaxel alone were assessed for oral hygiene by quantifying the number of oral bacteria they harbored. These patients received professional oral health care (POHC). Eighteen patients underwent primary prophylaxis with granulocyte colony-stimulating factors. The relationship between oral bacteria count and FN incidence was retrospectively assessed. Results The FN incidence rate was 47.4% throughout all treatment cycles (32.8%, 13.5%, 14.3%, and 14.4% in cycles 1, 2, 3, and 4, respectively). The oral bacteria count decreased with each treatment cycle (cycle 1: 9.10 × 106 colony-forming units (CFU)/mL, cycle 2: 5.89 × 106 CFU/mL, cycle 3: 4.61 × 106 CFU/mL, cycle 4: 5.85 × 106 CFU/mL, P = 0.004). Among 281 treatment cycles, FN occurred in 63 (22.4%). In the treatment cycle-based analysis, high oral bacteria count was an independent risk factor for FN. Conclusion FN incidence decreased with each treatment cycle and was associated with changes in oral bacteria counts. The oral bacterial count was one of risk factors for FN development in breast cancer.
- 21 October 2022
- Published by Springer Nature in Breast Cancer
- Vol. 30 (1) , 151-155
Impact of oral hygiene on febrile neutropenia during breast cancer chemotherapy
Purpose Oral hygiene is crucial in the management of oral and febrile complications during chemotherapy for cancer. This study aimed to investigate the impact of oral hygiene on the incidence of febrile neutropenia (FN) throughout the course of chemotherapy for breast cancer. Methods A total of 137 patients with breast cancer who underwent four cycles of adjuvant chemotherapy with docetaxel and cyclophosphamide (TC) combination therapy or docetaxel alone were assessed for oral hygiene by quantifying the number of oral bacteria they harbored. These patients received professional oral health care (POHC). Eighteen patients underwent primary prophylaxis with granulocyte colony-stimulating factors. The relationship between oral bacteria count and FN incidence was retrospectively assessed. Results The FN incidence rate was 47.4% throughout all treatment cycles (32.8%, 13.5%, 14.3%, and 14.4% in cycles 1, 2, 3, and 4, respectively). The oral bacteria count decreased with each treatment cycle (cycle 1: 9.10 × 106 colony-forming units (CFU)/mL, cycle 2: 5.89 × 106 CFU/mL, cycle 3: 4.61 × 106 CFU/mL, cycle 4: 5.85 × 106 CFU/mL, P = 0.004). Among 281 treatment cycles, FN occurred in 63 (22.4%). In the treatment cycle-based analysis, high oral bacteria count was an independent risk factor for FN. Conclusion FN incidence decreased with each treatment cycle and was associated with changes in oral bacteria counts. The oral bacterial count was one of risk factors for FN development in breast cancer.
- 1 July 2021
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 47 (7) , 1588-1592
Breast cancer detection by dedicated breast positron emission tomography according to the World Health Organization classification of breast tumors
- 1 July 2021
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 47 (7) , 1588-1592
Breast cancer detection by dedicated breast positron emission tomography according to the World Health Organization classification of breast tumors
- Open Access
- 5 May 2021
- Published by Springer Nature in Research Square
18 F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Predicts the Function of Tumor Immune Microenvironment in Early Triple-Negative Breast Cancer
BackgroundThe maximum standardized uptake value (SUVmax) on 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) is presumed to visualize not only tumor cells but also active immune cells in the tumor microenvironment based on their glycolysis activity. This study aimed to investigate the relationship between SUVmax on FDG PET/CT and tumor-infiltrating lymphocyte (TIL) subsets.MethodsFifty-four patients with invasive triple-negative breast cancer (TNBC) underwent FDG PET/CT before neoadjuvant chemotherapy, and pre-treatment biopsy specimens were pathologically evaluated. The expression status of CD8, forkhead box P3 (FOXP3), programmed cell death-1 (PD-1), and programmed cell death-ligand 1 (PD-L1) were assessed by immunohistochemistry. The relationship between TIL subsets and SUVmax or pathological complete response (pCR) was investigated.ResultsTILs, CD8, FOXP3, PD-1, and PD-L1 were high in 15 (27.8%), 15 (27.8%), 39 (72.2%), 18 (33.3%), and 26 (48.2%) patients, respectively. SUVmax was significantly correlated with tumor size, Ki-67 labeling index, and CD8/FOXP3 ratio (P = 0.003, P = 0.043, and P = 0.017, respectively). In multiple linear regression analysis, tumor size and CD8/FOXP3 ratio predicted SUVmax (P < 0.001 and P = 0.045, respectively). Seventeen patients (31.5%) achieved a pCR. TILs, CD8/FOXP3 ratio, PD-1, and PD-L1 were significantly correlated with the pCR rate. In multivariate analysis, the CD8/FOXP3 ratio was the only independent predictive factor for pCR (P = 0.010).ConclusionSUVmax on FDG PET/CT was related to tumor biological factors and the immune microenvironment after adjusting for confounding factors in TNBC. FDG uptake was influenced by the CD8/FOXP3 ratio, which predicts pCR after neoadjuvant chemotherapy.
- 5 May 2021
- Published by Springer Nature in Research Square
Open Access18 F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Predicts the Function of Tumor Immune Microenvironment in Early Triple-Negative Breast Cancer
BackgroundThe maximum standardized uptake value (SUVmax) on 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) is presumed to visualize not only tumor cells but also active immune cells in the tumor microenvironment based on their glycolysis activity. This study aimed to investigate the relationship between SUVmax on FDG PET/CT and tumor-infiltrating lymphocyte (TIL) subsets.MethodsFifty-four patients with invasive triple-negative breast cancer (TNBC) underwent FDG PET/CT before neoadjuvant chemotherapy, and pre-treatment biopsy specimens were pathologically evaluated. The expression status of CD8, forkhead box P3 (FOXP3), programmed cell death-1 (PD-1), and programmed cell death-ligand 1 (PD-L1) were assessed by immunohistochemistry. The relationship between TIL subsets and SUVmax or pathological complete response (pCR) was investigated.ResultsTILs, CD8, FOXP3, PD-1, and PD-L1 were high in 15 (27.8%), 15 (27.8%), 39 (72.2%), 18 (33.3%), and 26 (48.2%) patients, respectively. SUVmax was significantly correlated with tumor size, Ki-67 labeling index, and CD8/FOXP3 ratio (P = 0.003, P = 0.043, and P = 0.017, respectively). In multiple linear regression analysis, tumor size and CD8/FOXP3 ratio predicted SUVmax (P < 0.001 and P = 0.045, respectively). Seventeen patients (31.5%) achieved a pCR. TILs, CD8/FOXP3 ratio, PD-1, and PD-L1 were significantly correlated with the pCR rate. In multivariate analysis, the CD8/FOXP3 ratio was the only independent predictive factor for pCR (P = 0.010).ConclusionSUVmax on FDG PET/CT was related to tumor biological factors and the immune microenvironment after adjusting for confounding factors in TNBC. FDG uptake was influenced by the CD8/FOXP3 ratio, which predicts pCR after neoadjuvant chemotherapy.
- 4 November 2020
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 29 (7) , 3507-3512
Febrile neutropenia and role of prophylactic granulocyte colony-stimulating factor in docetaxel and cyclophosphamide chemotherapy for breast cancer
Purpose Febrile neutropenia (FN) incidence during docetaxel and cyclophosphamide (TC) chemotherapy, known as a high-risk regimen, differs among countries. The role of prophylactic granulocyte colony-stimulating factor (G-CSF) in FN is unclear. This study aimed to investigate FN frequency and relative dose intensity (RDI) of TC chemotherapy in patients with breast cancer and identify the correct population requiring prophylactic G-CSF. Methods In total, 205 patients with breast cancer were scheduled for TC chemotherapy (docetaxel/cyclophosphamide 75/600 mg/m2, every 3 weeks, 4 cycles) as adjuvant chemotherapy. Trastuzumab (8 mg/kg; continued with 6 mg/kg) was administrated intravenously for human epidermal growth factor receptor 2 (HER2)-positive cancer. Fifty-five patients received primary prophylactic measures (G-CSF: 20 and antibiotics: 35). We investigated the frequency of FN and hospitalization, RDI, and the factors related to FN, adverse events, hospitalization, and RDI. Results FN occurred in 70 patients (35.7%). FN incidence was noted in 41.1% without any prophylactic measures and in 5.0% with prophylactic G-CSF. In multivariate analysis, the independent risk factors of FN were older age (≥ 60 years, P = 0.017) and without primary prophylactic G-CSF (P = 0.011). Eleven patients (5.6%) were hospitalized of which 8 (72.7%) were elderly. The median RDIs of docetaxel and cyclophosphamide were 96.7% and 99.7%, respectively. Conclusion FN frequency during TC chemotherapy was high, and primary prophylactic G-CSF reduced FN incidence. Primary prophylactic G-CSF is an effective therapy for preventing FN during TC chemotherapy. However, prophylactic G-CSF should be considered for elderly patients based on the low hospitalization rate and the high RDI.
- 4 November 2020
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 29 (7) , 3507-3512
Febrile neutropenia and role of prophylactic granulocyte colony-stimulating factor in docetaxel and cyclophosphamide chemotherapy for breast cancer
Purpose Febrile neutropenia (FN) incidence during docetaxel and cyclophosphamide (TC) chemotherapy, known as a high-risk regimen, differs among countries. The role of prophylactic granulocyte colony-stimulating factor (G-CSF) in FN is unclear. This study aimed to investigate FN frequency and relative dose intensity (RDI) of TC chemotherapy in patients with breast cancer and identify the correct population requiring prophylactic G-CSF. Methods In total, 205 patients with breast cancer were scheduled for TC chemotherapy (docetaxel/cyclophosphamide 75/600 mg/m2, every 3 weeks, 4 cycles) as adjuvant chemotherapy. Trastuzumab (8 mg/kg; continued with 6 mg/kg) was administrated intravenously for human epidermal growth factor receptor 2 (HER2)-positive cancer. Fifty-five patients received primary prophylactic measures (G-CSF: 20 and antibiotics: 35). We investigated the frequency of FN and hospitalization, RDI, and the factors related to FN, adverse events, hospitalization, and RDI. Results FN occurred in 70 patients (35.7%). FN incidence was noted in 41.1% without any prophylactic measures and in 5.0% with prophylactic G-CSF. In multivariate analysis, the independent risk factors of FN were older age (≥ 60 years, P = 0.017) and without primary prophylactic G-CSF (P = 0.011). Eleven patients (5.6%) were hospitalized of which 8 (72.7%) were elderly. The median RDIs of docetaxel and cyclophosphamide were 96.7% and 99.7%, respectively. Conclusion FN frequency during TC chemotherapy was high, and primary prophylactic G-CSF reduced FN incidence. Primary prophylactic G-CSF is an effective therapy for preventing FN during TC chemotherapy. However, prophylactic G-CSF should be considered for elderly patients based on the low hospitalization rate and the high RDI.